The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE
Open accessAbstract
Liver X receptors (LXRs) alpha and beta are transcriptional regulators of cholesterol homeostasis and potential targets for the development of antiatherosclerosis drugs. However, the specific roles of individual LXR isotypes in atherosclerosis and the pharmacological effects of synthetic agonists remain unclear. Previous work has shown that mice lacking LXRalpha accumulate cholesterol in the liver but not in peripheral tissues. In striking contrast, we demonstrate here that LXRalpha(-/-)apoE(-/-) mice exhibit extreme cholesterol accumulation in peripheral tissues, a dramatic increase in whole-body cholesterol burden, and accelerated atherosclerosis. The phenotype of these mice suggests that the level of LXR pathway activation in macrophages achieved by LXRbeta and endogenous ligand is unable to maintain homeostasis in the setting of hypercholesterolemia. Surprisingly, however, a highly efficacious synthetic agonist was able to compensate for the loss of LXRalpha. Treatment of LXRalpha(-/-)apoE(-/-) mice with synthetic LXR ligand ameliorates the cholesterol overload phenotype and reduces atherosclerosis. These observations indicate that LXRalpha has an essential role in maintaining peripheral cholesterol homeostasis in the context of hypercholesterolemia and provide in vivo support for drug development strategies targeting LXRbeta.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
Self-citationLiver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
Self-citation
Cited by
Macrophage Phenotype and Function in Different Stages of Atherosclerosis
Tabas, I., & Bornfeldt, K. E. (2016) · Circulation Research · doi:10.1161/circresaha.115.306256 · Cited by 1,121
Macrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Bensinger, S. J., & Tontonoz, P. (2008) · Nature · doi:10.1038/nature07202 · Cited by 810
Self-citationTranscriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779
“When challenged with hypercholesterolaemia, mice lacking LXRs exhibit massive peripheral cholesterol accumulation and markedly accelerated atherosclerosi”
BackgroundSelf-citationRayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
Self-citationHDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Tall, A. R. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01898.x · Cited by 436
Little Fish, Big Data: Zebrafish as a Model for Cardiovascular and Metabolic Disease
Gut, P., Reischauer, S., Stainier, D. Y. R., & Arnaout, R. (2017) · Physiological Reviews · doi:10.1152/physrev.00038.2016 · Cited by 333
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers
Villa, G. R., Hulce, J. J., Zanca, C., Bi, J., Ikegami, S., Cahill, G. L., Gu, Y., Lum, K. M., Masui, K., Yang, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.008 · Cited by 325
Self-citationFernández-Hernando, C., Suárez, Y., Rayner, K. J., & Moore, K. J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283428d9d · Cited by 308
Liver X receptor biology and pharmacology: new pathways, challenges and opportunities
Jakobsson, T., Treuter, E., Gustafsson, J.-Å., & Steffensen, K. R. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.013 · Cited by 302
Liver X Receptor Signaling Pathways and Atherosclerosis
Calkin, A. C., & Tontonoz, P. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.191197 · Cited by 293
Self-citationRegulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
Rigamonti, E., Chinetti-Gbaguidi, G., & Staels, B. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.158998 · Cited by 293
Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors
Hong, C., & Tontonoz, P. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.07.016 · Cited by 253
Self-citationSallam, T., Jones, M., Thomas, B. J., Wu, X., Gilliland, T., Qian, K., Eskin, A., Casero, D., Zhang, Z., Sandhu, J., et al. (2018) · Nature Medicine · doi:10.1038/nm.4479 · Cited by 253
Self-citationLiver X receptors link lipid metabolism and inflammation
Schulman, I. G. (2017) · FEBS Letters · doi:10.1002/1873-3468.12702 · Cited by 244
Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis
Sallam, T., Jones, M. C., Gilliland, T., Zhang, L., Wu, X., Eskin, A., Sandhu, J., Casero, D., Vallim, T. Q. D. A., Hong, C., et al. (2016) · Nature · doi:10.1038/nature17674 · Cited by 212
Self-citationVenteclef, N., Jakobsson, T., Ehrlund, A., Damdimopoulos, A., Mikkonen, L., Ellis, E., Nilsson, L.-M., Parini, P., Jänne, O. A., Gustafsson, J.-Å., et al. (2010) · Genes & Development · doi:10.1101/gad.545110 · Cited by 178
The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease
Fessler, M. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.010 · Cited by 173
Kirchgessner, T. G., Sleph, P., Ostrowski, J., Lupisella, J., Ryan, C. S., Liu, X., Fernando, G., Grimm, D., Shipkova, P., Zhang, R., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.016 · Cited by 172
Insulin resistance and altered systemic glucose metabolism in mice lacking Nur77
Chao, L. C., Wroblewski, K., Zhang, Z., Pei, L., Vergnes, L., Ilkayeva, O. R., Ding, S. Y., Reue, K., Watt, M. J., Newgard, C. B., et al. (2009) · Diabetes · doi:10.2337/db09-0763 · Cited by 154
Self-citationNovel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways
A-González, N., & Castrillo, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.015 · Cited by 139
Liver X receptors (LXR) as therapeutic targets in dyslipidemia
Bełtowski, J. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00062.x · Cited by 132
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
LXRα Regulates Macrophage Arginase 1 Through PU.1 and Interferon Regulatory Factor 8
Pourcet, B., Feig, J. E., Vengrenyuk, Y., Hobbs, A. J., Kepka-Lenhart, D., Garabedian, M. J., Morris, S. M., Fisher, E. A., & Pineda-Torra, I. (2011) · Circulation Research · doi:10.1161/circresaha.111.241810 · Cited by 97
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
Griffett, K., Welch, R. D., Flaveny, C. A., Kolar, G. R., Neuschwander-Tetri, B. A., & Burris, T. P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.009 · Cited by 95
Bischoff, E. D., Daige, C. L., Petrowski, M., Dedman, H., Pattison, J., Juliano, J., Li, A. C., & Schulman, I. G. (2010) · The Journal of Lipid Research · doi:10.1194/jlr.m900096 · Cited by 91
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y.-W., & Konrad, R. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100068 · Cited by 82
ElAli, A., & Hermann, D. M. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00517.x · Cited by 74
Barylski, M., Toth, P. P., Nikolic, D., Banach, M., Rizzo, M., & Montalto, G. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.11.001 · Cited by 67
Matsumoto, K., Chiba, Y., Fujihara, R., Kubo, H., Sakamoto, H., & Ueno, M. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1366-7 · Cited by 46
Peng, D., Hiipakka, R. A., Xie, J., Dai, Q., Kokontis, J. M., Reardon, C. A., Getz, G. S., & Liao, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01202.x · Cited by 39
Yoon, H.-S., Ju, J.-H., Kim, H.-N., Park, H.-J., Ji, Y., Lee, J.-E., Shin, H.-K., Do, M.-S., & Holzapfel, W. (2013) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2012.706598 · Cited by 38
miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches
Price, N. L., Goedeke, L., Suárez, Y., & Fernández‐Hernando, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012606 · Cited by 36
The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis
Sallam, T., Ito, A., Rong, X., Kim, J., van Stijn, C., Chamberlain, B. T., Jung, M. E., Chao, L. C., Jones, M., Gilliland, T., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m047548 · Cited by 30
Self-citationCalkin, A. C., Lee, S. D., Kim, J., Van Stijn, C. M. W., Wu, X.-H., Lusis, A. J., Hong, C., Tangirala, R. I., & Tontonoz, P. (2014) · Circulation Research · doi:10.1161/circresaha.115.304440 · Cited by 27
Self-citationLiver X receptors: From pharmacology to nanoparticle-based drug delivery
Hua, X., & Wei, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175953 · Cited by 14
Metadata
- Authors
- Bradley, M. N., Hong, C., Chen, M., Joseph, S. B., Wilpitz, D. C., Wang, X., Lusis, A. J., Collins, A., Hseuh, W. A., Collins, J. L., Tangirala, R. K., & Tontonoz, P.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-08-01
- Volume
- 117
- Issue
- 8
- Pages
- 2337-2346
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1963825605
- Cited by
- 250
- References
- 5
- FWCI
- 21.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.